BioSpace News Archive

10x Genomics announced the company will be participating in the upcoming BofA Securities Virtual Healthcare Conference.

iCAD, Inc. announced that it will release financial results for the first quarter ended March 31, 2020, after the market close, and host a conference call at 4:30 pm Eastern Time on Monday, May 11.

Prevail Therapeutics Inc. announced that Asa Abeliovich, M.D., Ph.D., Founder and Chief Executive Officer, will participate in a fireside chat at the Bank of America Global Research Virtual Health Care Conference 2020 on Tuesday, May 12, 2020 at 11:40 a.m.

ArTara Therapeutics, Inc., a development-stage clinical biopharmaceutical company developing treatments for rare and specialty diseases with significant unmet needs, announced the grants of inducement non-qualified stock options to purchase an aggregate of 4,100 shares of common stock to two new employees.

Delcath Systems, Inc., an interventional oncology company focused on the treatment of rare primary and metastatic cancers of the liver, announced the closing of its previously announced underwritten public offering of 2.2 million shares of common stock and Series F warrants to purchase up to 2.2 million shares of common stock.

T2 Biosystems, Inc., a leader in the rapid detection of sepsis-causing pathogens, announced financial results for the first quarter ended March 31, 2020.

Aptose Biosciences Inc., a clinical-stage company developing highly differentiated agents that target the underlying mechanisms of cancer, announced financial results and corporate update for the three months ended March 31, 2020.

Kura Oncology, Inc., a clinical-stage biopharmaceutical company committed to realizing the promise of precision medicines for the treatment of cancer, announced that it has commenced an underwritten public offering, subject to market and other conditions, to issue and sell shares of its common stock.

Rhythm Pharmaceuticals, Inc. (Nasdaq: RYTM), a late-stage biopharmaceutical company aimed at developing and commercializing therapies for the treatment of rare genetic disorders of obesity, today announced that Hunter Smith, Interim Chief Executive Officer and Chief Financial Officer of Rhythm, and, Murray Stewart, M.D., Chief Medical Officer of Rhythm, will participate in a fireside chat at the 2020 BofA Securities Health Care Conference on Tuesday, Ma

Selecta Biosciences, Inc. (NASDAQ: SELB), a clinical-stage biotechnology company focused on unlocking the full potential of biologic therapies based on its immune tolerance platform, ImmTOR™, today announced that Selecta’s Chief Executive Officer, Carsten Brunn, Ph.D., will present at the Bank of America Merrill Lynch 2020 Health Care Conference, which is being held virtually, on Tuesday, May 12 at 5:00 p.m. Eastern Time. A live webcast an